Q32 Bio Inc.
QTTB•NASDAQ•Healthcare•Biotechnology

About Q32 Bio

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJodie Morrison
Founded2015
Employees43
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.q32bio.com
Phone781 999 0232
Address
830 Winter Street Waltham, Massachusetts 02451 United States

Corporate Identifiers

CIK0001661998
CUSIP746964105
ISINUS7469641051
EIN47-3468154
SIC2834

Leadership Team & Key Executives

Jodie Pope Morrison
Chief Executive Officer and Director
Lee H. Kalowski M.B.A.
Chief Financial Officer and President
Dr. Shelia M. Violette Ph.D.
Co-founder, Chief Scientific Officer and President of Research
Dr. Saul W. Fink Ph.D.
Chief Technology Officer
David Appugliese J.D.
Senior Vice President and Head of People
Maria Marzilli M.P.H.
Executive Vice President of Corporate Strategy and Program Operations
Dr. Adrien Sipos
Interim Chief Medical Officer